(Q37801276)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Growth hormone, the insulin-like growth factor axis, insulin and cancer risk (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Philip G. Murray

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Andrew G. Renehan

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Indraneel Banerjee

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

19 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

11-24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2010.171

15 February 2020

exact match

0 references

cites work

Role of insulin-like growth factors in embryonic and postnatal growth

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Obesity and colorectal cancer risk: a meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Hypophysectomy in the treatment of malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during beta-cell tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Overexpression of human insulin-like growth factor-II in transgenic mice causes increased growth of the thymus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Disproportionate growth in mice with Igf-2 transgenes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Co-expression of GH and GHR isoforms in prostate cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

High stromal and epithelial human gh gene expression is associated with proliferative disorders of the mammary gland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Growth hormone receptor expression in human colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Growth hormone receptor overexpression predicts response of rectal cancers to pre-operative radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Antagonists of growth hormone-releasing hormone in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Effect of hypoxia on lung, heart, and liver insulin-like growth factor-I gene and receptor expression in the newborn rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Transport of insulin-like growth factor-I across endothelial cell monolayers and its binding to the subendothelial matrix

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

IGF-1 regulates migration and angiogenesis of human endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Disrupting insulin-like growth factor signaling as a potential cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Role of the insulin-like growth factor family in cancer development and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

The effect of cigarette smoking use and cessation on serum insulin-like growth factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Cellular actions of the insulin-like growth factor binding proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Acromegaly and cancer risk: a cohort study in Sweden and Denmark.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Increased cancer incidence in acromegaly--a nationwide survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Acromegaly and gastrointestinal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Acromegaly, growth hormone and cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Growth hormone treatment and cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Long-term safety of recombinant human growth hormone in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Morbidity and GH deficiency: a nationwide study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Safety aspects of GH replacement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Hyperactive Ras in developmental disorders and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Leukemia in Growth-Hormone Treated Patients: An Update, 1992

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin injections promote the growth of aberrant crypt foci in the colon of rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Aberrant crypt focus promotion and glucose intolerance: correlation in the rat across diets differing in fat, n-3 fatty acids and energy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Growth inhibition of rat mammary carcinoma and endocrine changes produced by 2-Br-alpha-ergocryptine, a suppressor of lactation and nidation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of th

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Central obesity and breast cancer risk: a systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Biological mechanisms linking obesity and cancer risk: new perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

31 March 2020

Insulin and colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Obesity and cancer risk: the role of the insulin-IGF axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Diabetes mellitus and risk of breast cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

A meta-analysis of diabetes mellitus and the risk of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Metformin and reduced risk of cancer in diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin glargine and malignancy: an unwarranted alarm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Does diabetes therapy influence the risk of cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin dependence of murine T-cell lymphoma. II. Insulin-deficient diabetic mice and mice fed low-energy diet develop resistance to lymphoma growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factor binding protein-1 over-expression in transgenic mice inhibits hepatic preneoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Does growth hormone treatment affect the risk of post-transplant renal cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Risk of leukemia in children treated with human growth hormone: review and reanalysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Lessons from the national cooperative growth study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.171

Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth.

31 March 2020

1 reference

12 December 2020

Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice.

1 reference

12 December 2020

Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience

1 reference

12 December 2020

Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction

1 reference

12 December 2020

Growth hormone and neurofibromatosis

1 reference

12 December 2020

Insulin promotion of colon tumors in rats.

1 reference

12 December 2020

Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice

1 reference

12 December 2020

PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?

1 reference

12 December 2020

Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation

1 reference

12 December 2020

Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin

1 reference

12 December 2020

Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.

1 reference

12 December 2020

Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies

1 reference

12 December 2020

Insulin-like growth factor-binding protein-3 in osteosarcomas and normal bone tissues

1 reference

12 December 2020

Leukemia and other malignancies among GH users

1 reference

12 December 2020

Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2.

1 reference

12 December 2020

Modulation of the immune response and tumor growth by activated Ras.

1 reference

12 December 2020

Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.

1 reference

12 December 2020

Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone

1 reference

12 December 2020

Neoplasms in rats treated with pituitary growth hormone; adrenal glands.

1 reference

12 December 2020

Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.

1 reference

12 December 2020

Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma

1 reference

12 December 2020

Growth hormone safety update from the National Cooperative Growth Study

1 reference

12 December 2020

Growth hormone treatment of children with brain tumors and risk of tumor recurrence.

1 reference

12 December 2020

Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.

1 reference

12 December 2020

Neoplasms in rats treated with pituitary growth hormone; pulmonary and lymphatic tissues.

1 reference

12 December 2020

Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone

1 reference

12 December 2020

Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis

1 reference

12 December 2020

Neoplasms in rats treated with pituitary growth hormone. III. Reproductive organs

1 reference

12 December 2020

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

12 December 2020

Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2010.171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956999%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference